Loading…
← CockpitCompetitor Analysis › 300896.SZ IMEIK Technology Development Co., Ltd. Class AOpen in the cockpit ↗

IMEIK Technology Development Co., Ltd. Class A300896.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Specialty

Chinese medical-aesthetics company making injectable hyaluronic-acid dermal fillers (TradingView's specialty-chemicals label understates its health-care nature).

≈ A Chinese Allergan Aesthetics (dermal fillers)/GaldermaMomentum neutral 44
Mkt cap
$3.66B
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$41.4M
20-day average traded
Fwd P/E
22.4×
forward earnings
ROIC−WACC
+3.7 pp
WACC 11.1%
Hurdle
-10 pp
Req g minus delivered
Next earnings
112 days
10 Mar 2027
Close · CNYCN¥85.27
1D-0.6%
1W-2.4%
1M-13.8%
3M-17.5%
6M-24.9%
YTD-39.8%
1Y-43.9%
ATR %3.5%
52w lowhigh47.6% off high

What IMEIK Technology Development does

Chinese medical-aesthetics company making injectable hyaluronic-acid dermal fillers (TradingView's specialty-chemicals label understates its health-care nature).

Sells injectable fillers to clinics and hospitals, with each product needing approval from China's drug regulator as a medical device, so its approved range, not factory output, limits sales. Clinics, not patients, are the direct buyers, so doctors' preference matters.

In one line: A Chinese Allergan Aesthetics (dermal fillers)/Galderma.

Products and services

  • Hyaluronic acid dermal fillers
  • Other aesthetic-medicine products

Customers

  • Aesthetic/dermatology clinics
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Medical aesthetics
  • Injectable dermal fillers

What could go right

  • Rising med-aesthetics consumer demand in China

What could go wrong

  • Increasing domestic/import filler competition
  • Regulatory pricing scrutiny in aesthetics

Moat: narrow (regulatory licence, brand, IP / patents). Regulatory approval for injectable fillers is slow to obtain; IMEIK holds one of the broadest approved filler portfolios in China.

Headquarters: Beijing, China · Employees: 1,458

Named competitors

IMEIK Technology Development at a glance

Size IMEIK Technology Development (300896.SZ) is a China Materials company (Chemicals: Specialty) with a market value of $3.66B, the 657th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥85.27 on 18 Nov 2026.

Performance Over six months the shares fell 24.9%, against -25.7% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue fell 7.3% over the last twelve months (peer median +10.9%); the operating margin is 44.6% (peer median 12.0%).

Valuation It trades at 22.4× forward earnings against a peer median of 14.9× (8th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.7 points above its cost of capital (11.1% WACC).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026300896.SZ 79Peer median 77
Six months, rebased to 100: IMEIK Technology Development against the median of its 20 peers (local-currency closes).

IMEIK Technology Development financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.33BCN¥2.42BCN¥3.01BCN¥2.86BCN¥1.93B
Revenue growth—-20%+5%+48%—
Gross profitCN¥2.16BCN¥2.19BCN¥2.80BCN¥2.67BCN¥1.81B
EBITDAn/aCN¥1.39BCN¥2.20BCN¥2.11BCN¥1.40B
Net incomeCN¥989MCN¥1.29BCN¥1.96BCN¥1.86BCN¥1.26B
Free cash flowCN¥888MCN¥1.22BCN¥1.74BCN¥1.92BCN¥1.06B
Capital expenditureCN¥191MCN¥171MCN¥239MCN¥63.7MCN¥156M
Total debtCN¥31.9MCN¥32.1MCN¥45.0MCN¥52.5MCN¥59.7M

Quarterly statements and history in the cockpit →

IMEIK Technology Development competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-10%0%+10%00240700243060029944030006294182688065CBT688300000683600884002340603379HWKNCLN600301HPOL-B40881402688548300896.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. IMEIK Technology Development is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×00240700243060029944030006294182688065CBT688300000683600884002340603379HWKNCLN60030140881402688548300896.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IMEIK Technology Development is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%0024070024306002994403000629CBT688300600884002340603379HWKNCLN600301HPOL-B40881402300896.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. IMEIK Technology Development is the large dot.

IMEIK Technology Development competitors and peer comparison

Head to head with its named competitors (300896.SZ vs 688363.SS vs ABBV vs GALD.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
IMEIK Technology Development 300896.SZ$3.66B-25%-7%45%22.4×17.5%
Bloomage Biotechnology 688363.SS$2.27B-21%-22%5%52.0×19.0%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
Galderma GALD.SW$51.9B+18%+16%19%45.7×18.0%

How IMEIK Technology Development compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IMEIK Technology Development against its 20 peers (data as of 18 Nov 2026)
Measure300896.SZPeer medianRank in peer set
1-month return-13.8%-4.3%4th lowest of 21
6-month return-24.9%-25.7%10th highest of 21
Distance from 52-week high-47.6%-41.9%5th lowest of 21
Revenue growth (TTM)-7.3%+10.9%lowest of 21
Operating margin44.6%12.0%highest of 21
Forward P/E22.4×14.9×8th most expensive of 21
Growth the price implies (Req g, 7 yrs)17.5%3.6%3rd most demanding of 17
Growth delivered (Del g)+28.0%+8.4%2nd highest of 17
Hurdle (Req g minus delivered)-10.5 pp-4.4 pp7th least demanding of 17
ROIC minus cost of capital+3.7 pp+1.8 pp8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
IMEIK Technology Development 300896.SZChina$3.66B-25%-7%45%22.4×17.5%+28.0%
Do-Fluoride New Materials 002407.SZChina$3.62B-42%+69%7%33.9×17.3%+17.5%
Hangzhou Oxygen Plant 002430.SZChina$3.70B-16%+16%11%19.8×2.2%+8.5%
Bluestar Adisseo 600299.SSChina$3.70B-34%+15%13%11.3×-9.4%+7.7%
NOF 4403.TJapan$3.60B-10%+22%17%13.6×-7.4%+8.4%
Pangang Group Vanadium & Titanium Resources 000629.SZChina$3.60B-26%+6%4%57.3×26.1%-3.4%
Mitsubishi Gas Chemical 4182.TJapan$3.76B-32%+9%9%10.2×n/an/a
Cathay Biotech 688065.SSChina$3.77B-23%+9%18%34.3×n/an/a
Cabot CBTUnited States$3.80B-5%+1%14%11.3×-2.3%+1.9%
Novoray 688300.SSChina$3.40B-39%+23%26%49.8×45.5%+22.6%
Inner Mongolia Berun Chemical 000683.SZChina$3.28B-27%+11%13%13.8×n/an/a
Ningbo Shanshan 600884.SSChina$3.27B-35%+30%9%12.2×2.8%+21.3%
GEM 002340.SZChina$4.12B-35%+2%7%14.6×3.5%+24.4%
Zhejiang Sanmei Chemical Industry 603379.SSChina$4.20B-27%+24%41%12.2×3.8%+16.5%
Hawkins HWKNUnited States$3.19B-1%+9%11%34.4×15.9%+12.7%
Clariant CLN.SWSwitzerland$4.20B+35%-7%10%16.3×-3.3%+0.3%
Guangxi Huaxi Nonferrous Metal 600301.SSChina$4.27B-25%+24%32%22.6×9.1%+44.9%
Hexpol HPOL-B.STSweden$3.10B+19%-1%14%15.2×2.9%+7.6%
Air Water 4088.TJapan$4.34B+34%+11%3%11.8×9.4%+6.8%
Far Eastern New Century 1402.TWTaiwan$4.39B+2%+5%7%11.5×4.7%+4.2%
Guangzhou Guanggang Gases and Energy 688548.SSChina$3.02B-26%+21%20%55.4×n/an/a

Questions

Who are IMEIK Technology Development's main competitors?
Named competitors: Bloomage Biotechnology (688363.SS), AbbVie (Allergan Aesthetics) (ABBV), Galderma Group (GALD.SW). The cockpit's measured peer set (industry) also includes Do-Fluoride New Materials (002407.SZ), Hangzhou Oxygen Plant (002430.SZ), Bluestar Adisseo (600299.SS), NOF (4403.T), Pangang Group Vanadium & Titanium Resources (000629.SZ), Mitsubishi Gas Chemical (4182.T).
Is IMEIK Technology Development expensive compared with its peers?
On forward p/e it trades at 22.4× against a peer median of 14.9×, 8th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has IMEIK Technology Development stock performed?
Over six months to 18 Nov 2026 the shares returned -24.9% against -25.7% for the median peer; over one year -43.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.